{"entity":{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","aka":[],"tldr":"A phase 1/2 trial of Atezolizumab in small-cell lung cancer, run by Genprex, Inc., now recruiting.","summary":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients is a phase 1/2 interventional study registered as NCT05703971 by Genprex, Inc., with 62 participants planned, started 2024-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: quaratusugene ozeplasmid, atezolizumab. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05703971","url":"https://clinicaltrials.gov/study/NCT05703971"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab"],"companies":["genprex"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05703971","phase":"1/2","setting":"A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Genprex, Inc.","enrolled":62,"outcomes":[]},"route":"/trials/nct05703971/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"company":[{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/"}]}}